2022 | | BCL2 super-expressor diffuse large B-cell lymphoma: a distinct subgroup associated with poor prognosis | 노진, 정성현, 최윤석 |
2012 | | Clinical features and outcomes of Hodgkin's lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL) | 박준성 |
2003 | | Clinical significance of bone marrow micrometastasis detected by nested rt-PCR for keratin-19 in breast cancer patients. | 김명욱, 박준성, 박희붕, 소의영, 이국종, 임현이, 정용식 |
2014 | | Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: randomized phase II multicenter trial. | 강석윤 |
2020 | | DeepBTS: Prediction of Recurrence-free Survival of Non-small Cell Lung Cancer Using a Time-binned Deep Neural Network | 이현우 |
2002 | | Expression of multidrug resistance-associated protein1,P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. | 김명욱, 김효철, 이기범, 임호영, 조용관, 주희재, 최진혁 |
2012 | | Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study | 이현우 |
2003 | | High dose therapy followed by autologous peripheral blood stem cell transplantation as a first line treatment for multiple myeloma: a Korean Multicenter Study. | 김효철 |
2000 | | Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. | 김현수, 김효철, 남동기, 이기범, 임호영, 주희재, 최진혁 |
2011 | | Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy. | 박준성, 정성현 |
2015 | | Oral Maintenance Chemotherapy with 6-Mercaptopurine and Methotrexate in Patients with Acute Myeloid Leukemia Ineligible for Transplantation. | 강석윤, 박준성, 안미선, 이현우, 정성현, 최용원, 최진혁 |
2022 | | Oxaliplatin (3 months v 6 months) with 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients with Stage II/III Colon Cancer: KCSG CO09-07 | 강석윤 |
2016 | | Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008) | 정성현 |
2015 | | Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06). | 안미선 |
2012 | | Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study | 김효철 |
2013 | | Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02. | 강석윤 |
2021 | | Prognostic effects of cytokine levels on patients treated with taxane and zoledronic acid for metastatic breast cancer in bone (BEAT-ZO) (KCSG BR 10-13) | 강석윤 |
2016 | | Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study | 강석윤 |
2020 | | Quantitative analysis of tumor-specific BCL2 expression in DLBCL: refinement of prognostic relevance of BCL2 | 노진, 박준성, 정성현, 한재호 |
2023 | | Real-world data of long-term survival in patients with T-cell lymphoma who underwent stem cell transplantation | 박준성 |
2012 | | Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial | 박준성 |
2018 | | The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple Myeloma | 박준성, 정성현 |